Our paradigm also recognizes a subset of patients who might instead benefit from inhibition of cGAS–STING signalling to curb tumour-intrinsic chronic inflammation and its immune-suppressive sequalae (cGAShighSTINGlow, Fig. 5e,f). The gene discussed is CGAS; the disease is neoplasm.